GENEVA--(BUSINESS WIRE)--Acrongenomics Inc. (OTCBB:AGNM) announces today that it has appointed London based De Facto Communications to manage its public and investor relations from January 2008. De Facto’s appointment is a key part of the strategy to finalise the development and commercialisation of the point-of-care diagnostic device that the Company is in the process of fully acquiring. De Facto’s role will be to continue to build the reputation of Acrongenomics with all stakeholders in Europe and North America as the Company completes its acquisition of Molecular Vision Limited and moves towards earning its first revenues.
